SCHEMBL2818009

SCHEMBL2818009

CCCCCCCCCCCCCCCCOc1ccc(C=O)cc1OC

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.77
MAPT P10636 10/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
LMNA P02545 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
HTT P42858 2/20 0.62
ALDH1A1 P00352 13/20 0.62
TSHR P16473 1/20 0.62
CYP2C9 P11712 3/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
HPGD P15428 7/20 0.58
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
HSP90AA1 P07900 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
CYP2D6 P10635 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30360548 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL30360545 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL5689116 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL30360547 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL10417162 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL30360543 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL8310250 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL8907835 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL30360546 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL3041624 1.00 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118369310-A Sulfonate compounds 卡尔弗朗茨格拉茨大学 2024-07-19 CN disclosed
WO-2023046766-A1 NOVEL SULFONATE COMPOUNDS KARL FRANZENS UNIVERSITÄT GRAZ (AT) 2023-03-30 WO disclosed
US-10239839-B2 Compounds and formulations suitable for radical scavenging SOLENNE BV (NL) 2019-03-26 US disclosed
US-20170037012-A1 Compounds and Formulations Suitable for Radical Scavenging COMBRAY B.V. (NL) 2017-02-09 US disclosed
US-20170037012-A1 Compounds and Formulations Suitable for Radical Scavenging COMBRAY B.V. (NL) 2017-02-09 US disclosed
US-9475810-B2 Compounds and formulations suitable for radical scavenging SOLENNE BV (NL) 2016-10-25 US disclosed
US-9475810-B2 Compounds and formulations suitable for radical scavenging SOLENNE BV (NL) 2016-10-25 US disclosed
EP-2101574-B1 COMPOUNDS AND FORMULATIONS SUITABLE FOR RADICAL SCAVENGING SOLENNE BV (NL) 2016-07-13 EP disclosed
EP-2101574-B1 COMPOUNDS AND FORMULATIONS SUITABLE FOR RADICAL SCAVENGING SOLENNE BV (NL) 2016-07-13 EP disclosed
US-9196843-B2 Fullerene derivative, and method of preparing the same RICOH COMPANY, LTD. (JP) 2015-11-24 US disclosed
US-20140080853-A1 Compounds and Formulations Suitable for Radical Scavenging SOLENNE BV (NL) 2014-03-20 US disclosed
US-20140080853-A1 Compounds and Formulations Suitable for Radical Scavenging SOLENNE BV (NL) 2014-03-20 US disclosed
US-20140024839-A1 FULLERENE DERIVATIVE, AND METHOD OF PREPARING THE SAME RICOH COMPANY, LTD. (JP) 2014-01-23 US disclosed
US-8580810-B2 Compounds and formulations suitable for radical scavenging SOLENNE BV (NL) 2013-11-12 US disclosed
US-8580810-B2 Compounds and formulations suitable for radical scavenging SOLENNE BV (NL) 2013-11-12 US disclosed
US-20100249168-A1 Compounds and Formulations Suitable for Radical Scavenging SOLENNE BV (NL) 2010-09-30 US disclosed
EP-2101574-A2 COMPOUNDS AND FORMULATIONS SUITABLE FOR RADICAL SCAVENGING Solenne BV (NL) 2009-09-23 EP disclosed
WO-2008067436-A2 COMPOUNDS AND FORMULATIONS SUITABLE FOR RADICAL SCAVENGING SOLENNE BV (NL) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239839-B2 Compounds and formulations suitable for radical scavenging CBR1, FTO, AKR1A1 FDPS 1722/4885MAPT 2072/4885SMN1; SMN2 3139/4885
US-20100249168-A1 Compounds and Formulations Suitable for Radical Scavenging CBR1, QSOX1, GLO1 FDPS 875/4885MAPT 2639/4885SMN1; SMN2 2776/4885
US-20170037012-A1 Compounds and Formulations Suitable for Radical Scavenging CBR1, FTO, AKR1A1 FDPS 1722/4885MAPT 2072/4885SMN1; SMN2 3139/4885
US-20140080853-A1 Compounds and Formulations Suitable for Radical Scavenging CBR1, FTO, AKR1A1 FDPS 1722/4885MAPT 2072/4885SMN1; SMN2 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.